The global pathogen genomics and genomic surveillance market was valued at USD 2.36 billion in 2025. The market is estimated at USD 2.55 billion in 2026 and is projected to reach USD 6.12 billion by 2036, at a CAGR of 9.1% during the forecast period 2026-2036. This report provides a detailed assessment of the market, covering sequencing and bioinformatics technologies, surveillance programs, wastewater and One Health monitoring, clinical metagenomics, funding and data policy, post-pandemic normalization, cost per sample, the supplier landscape, and future growth opportunities.
The market covers the instruments, consumables, software, and services that laboratories use to sequence and interpret the genomes of viruses, bacteria, fungi, and parasites for surveillance, outbreak investigation, diagnosis, antimicrobial resistance (AMR) monitoring, food safety, and vaccine and drug work. It includes short-read and long-read sequencers, whole-genome, amplicon, and metagenomic library kits and pathogen panels, genomic epidemiology software, and sequencing services such as wastewater and traveler-based programs and clinical metagenomic testing. PCR-only syndromic and detection panels without sequencing, culture-based microbiology, serology, and human genomic sequencing are excluded.
By June 2026, the CDC's National Wastewater Surveillance System (NWSS) ran about 1,300 sites covering roughly 144 million people in the U.S. and monitored measles, mpox, RSV, and both seasonal and avian influenza in addition to SARS-CoV-2. February 2026 appropriations averted an immediate shortfall, yet the American Society for Microbiology has called for no less than USD 120 million for the program in fiscal 2027 as long-term support remains unsettled. Africa CDC's Africa Pathogen Genomics Initiative, backed by USD 100 million over four years from donors and companies such as Microsoft, Illumina, Oxford Nanopore Technologies, the Gates Foundation, and the U.S. CDC, has set up sequencing capacity in more than 20 African countries.
Many programs began on one-time emergency money, and its end has created budget cliffs that slow purchasing. Ginkgo Bioworks, which worked with the CDC on airport surveillance, reported a 30% drop in 2025 biosecurity revenue to USD 37.4 million and agreed to sell that unit to investors. Many laboratories, especially in low- and middle-income countries, lack trained sequencing, bioinformatics, and genomic epidemiology staff. Barriers to data sharing, differing methods and formats, and the need to prove value between outbreaks are further challenges.
Clinical metagenomic sequencing, which can find bacteria, viruses, fungi, and parasites in one test without knowing the cause, is a significant opportunity in complex infections. In April 2026, Karius made its Spectrum plasma and Focus BAL tests, which return results within 24 hours of sample receipt, available through Mayo Clinic Laboratories. One Health monitoring, capacity building in lower-income countries, and AI tools for variant assessment and automated analysis offer further openings. Key trends include the shift from SARS-CoV-2 to multi-pathogen surveillance, wider use of portable and long-read sequencing, and the growth of agnostic detection in clinical care and wastewater and traveler programs.
By offering, the pathogen genomics and genomic surveillance market is segmented into consumables & reagents, instruments, software & bioinformatics, and services, with services split into surveillance, clinical testing, and research sequencing services. Consumables & reagents are expected to hold the largest share in 2026, as library kits, panels, and sequencing chemistry are reordered with every run and the large fleet of sequencers installed during the pandemic keeps reagent use steady. Software & bioinformatics is projected to record the highest CAGR, supported by labs short of bioinformatics staff that need automated analysis, the linking of genomic and clinical data, and AI-enabled epidemiology tools. Instruments are expected to grow more slowly as laboratories draw on existing capacity.
By sequencing approach, the pathogen genomics and genomic surveillance market is segmented into whole-genome sequencing, targeted & amplicon sequencing, and metagenomic sequencing. Whole-genome sequencing leads in 2026, as it is the reference method for viral variant tracking, foodborne outbreak investigation, and resistance surveillance, and gives the full-genome resolution needed to link cases. Metagenomic sequencing is set to grow the fastest, driven by clinical metagenomic tests, unbiased screening of wastewater and traveler samples, and the need to catch new or unexpected pathogens.
By platform, the pathogen genomics and genomic surveillance market is segmented into short-read and long-read sequencing. Short-read sequencing holds the larger share in 2026, given its high accuracy and throughput and its established place in public health laboratories that run large surveillance volumes on platforms from Illumina and others. Long-read sequencing is projected to post the higher CAGR, as portable and fast nanopore devices work in field and low-resource settings and long reads resolve complete genomes, plasmids, and resistance genes.
By pathogen type, the pathogen genomics and genomic surveillance market is segmented into viruses, bacteria, fungi, and parasites. Viruses account for the largest share in 2026, reflecting continued monitoring of SARS-CoV-2, H5N1 and other influenza strains, RSV, measles, mpox, and HIV. Bacteria are projected to grow the fastest, as whole-genome sequencing spreads in AMR surveillance, foodborne outbreak work, tuberculosis drug resistance testing, and hospital infection control. Fungi are also expected to grow strongly as surveillance of drug-resistant fungal pathogens expands.
By application, the pathogen genomics and genomic surveillance market is segmented into outbreak detection & public health surveillance, wastewater & environmental surveillance, clinical infectious disease diagnostics, antimicrobial resistance monitoring, food safety & One Health surveillance, and vaccine & drug development. Outbreak detection & public health surveillance holds the largest share in 2026, since national and regional public health laboratories sequence routinely for variant tracking and outbreak response. Wastewater & environmental surveillance is set to grow the fastest, supported by the scale of NWSS, multi-pathogen expansion of wastewater programs, and international support such as International Pathogen Surveillance Network (IPSN) grants. Clinical infectious disease diagnostics should also grow strongly on metagenomic testing.
By end user, the pathogen genomics and genomic surveillance market is segmented into public health laboratories & government agencies, hospitals & clinical laboratories, academic & research institutes, pharmaceutical & biotechnology companies, and food, agriculture & animal health organizations. Public health laboratories & government agencies hold the largest share in 2026, as national and regional agencies run most genomic surveillance programs. Hospitals & clinical laboratories are projected to grow the fastest, driven by metagenomic diagnostics, sequencing to investigate healthcare-associated outbreaks, and resistance testing, which depend less on public health budgets.
North America is expected to hold the largest share of the global market in 2026, supported by large public health programs such as NWSS and the CDC Advanced Molecular Detection program, advanced clinical laboratories, and providers such as Illumina, Thermo Fisher Scientific, Twist Bioscience, and Karius. Since 2021, the CDC's airport program has tested voluntary traveler nasal swabs and aircraft and terminal wastewater at nine U.S. international airports for more than 30 viral and bacterial targets. Uncertain funding beyond fall 2026 may slow near-term growth, while Canada adds demand through national wastewater and genomic programs.
Asia-Pacific is projected to grow at the highest CAGR, driven by large populations, frequent zoonotic and respiratory threats, investment in public health and pandemic preparedness, and rising sequencing capacity. China is expected to lead the region on large public health and research programs and domestic sequencing suppliers, with strong growth also expected across Japan, Singapore, South Korea, Australia, and India. Europe holds a significant share through ECDC coordination, strong national programs, EU wastewater initiatives, and suppliers such as Oxford Nanopore Technologies, QIAGEN, and Eurofins; the UK Health Security Agency runs one of the most advanced programs, and Berlin hosts the WHO hub that houses IPSN. Latin America, led by Brazil and Mexico, and the Middle East & Africa, supported by the Africa Pathogen Genomics Initiative and public health genomics investment in the Gulf countries, hold smaller shares but are expected to grow strongly.
A small group of sequencing platform providers holds a significant share of the moderately consolidated pathogen genomics and genomic surveillance market, alongside reagent and panel suppliers such as Twist Bioscience, bioinformatics vendors, clinical metagenomic testing companies such as Karius, and surveillance service providers. Competition rests on turnaround time, throughput and cost per sample, portability, pathogen coverage, analysis and data-sharing tools, clinical regulatory status, and the ability to support public agencies and training programs. Leading players are developing multi-pathogen panels, portable sequencing, automated analysis, and clinical tests, often in partnership with public agencies and clinical laboratories. Recent developments include Karius' April 2026 launch through Mayo Clinic Laboratories, the WHO-hosted IPSN's second USD 1.8 million round of catalytic grants in April 2026, and Ginkgo Bioworks' agreement to sell its biosecurity business, which reflects the restructuring of pandemic-era surveillance services.
Key companies profiled in the report include Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), Oxford Nanopore Technologies plc (U.K.), QIAGEN N.V. (Netherlands), Twist Bioscience Corporation (U.S.), Eurofins Scientific SE (Luxembourg), Karius, Inc. (U.S.), and MGI Tech Co., Ltd. (China).
The market covers the instruments, consumables, software, and services that laboratories use to sequence and interpret the genomes of viruses, bacteria, fungi, and parasites for surveillance, outbreak investigation, diagnosis, antimicrobial resistance (AMR) monitoring, food safety, and vaccine and drug work. It includes short-read and long-read sequencers, whole-genome, amplicon, and metagenomic library kits and pathogen panels, genomic epidemiology software, and sequencing services such as wastewater and traveler-based programs and clinical metagenomic testing. PCR-only syndromic and detection panels without sequencing, culture-based microbiology, serology, and human genomic sequencing are excluded.
By June 2026, the CDC's National Wastewater Surveillance System (NWSS) ran about 1,300 sites covering roughly 144 million people in the U.S. and monitored measles, mpox, RSV, and both seasonal and avian influenza in addition to SARS-CoV-2. February 2026 appropriations averted an immediate shortfall, yet the American Society for Microbiology has called for no less than USD 120 million for the program in fiscal 2027 as long-term support remains unsettled. Africa CDC's Africa Pathogen Genomics Initiative, backed by USD 100 million over four years from donors and companies such as Microsoft, Illumina, Oxford Nanopore Technologies, the Gates Foundation, and the U.S. CDC, has set up sequencing capacity in more than 20 African countries.
Market Dynamics
Countries that built sequencing capacity for COVID-19 are now using it routinely for influenza, RSV, mpox, measles, foodborne pathogens, tuberculosis, and resistant bacteria, which makes the institutionalization of public health genomics a major driver of the pathogen genomics and genomic surveillance market. U.S. fiscal 2026 appropriations shifted NWSS and similar programs closer to permanent line-item funding. New and returning threats keep adding demand, including H5N1 in birds and dairy herds, where genomes from animals, milk, and retail dairy samples revealed repeated spillover, as well as mpox clade I, measles, and new SARS-CoV-2 variants. Wastewater sequencing gives an early, community-wide signal that does not rely on individual testing, and whole-genome sequencing has become standard for tracing Salmonella, Listeria, and E. coli outbreaks and tracking resistant strains.Many programs began on one-time emergency money, and its end has created budget cliffs that slow purchasing. Ginkgo Bioworks, which worked with the CDC on airport surveillance, reported a 30% drop in 2025 biosecurity revenue to USD 37.4 million and agreed to sell that unit to investors. Many laboratories, especially in low- and middle-income countries, lack trained sequencing, bioinformatics, and genomic epidemiology staff. Barriers to data sharing, differing methods and formats, and the need to prove value between outbreaks are further challenges.
Clinical metagenomic sequencing, which can find bacteria, viruses, fungi, and parasites in one test without knowing the cause, is a significant opportunity in complex infections. In April 2026, Karius made its Spectrum plasma and Focus BAL tests, which return results within 24 hours of sample receipt, available through Mayo Clinic Laboratories. One Health monitoring, capacity building in lower-income countries, and AI tools for variant assessment and automated analysis offer further openings. Key trends include the shift from SARS-CoV-2 to multi-pathogen surveillance, wider use of portable and long-read sequencing, and the growth of agnostic detection in clinical care and wastewater and traveler programs.
Segment Analysis
The report analyzes the market by offering, sequencing approach, platform, pathogen type, application, end user, and geography, helping stakeholders identify the most attractive growth areas.By offering, the pathogen genomics and genomic surveillance market is segmented into consumables & reagents, instruments, software & bioinformatics, and services, with services split into surveillance, clinical testing, and research sequencing services. Consumables & reagents are expected to hold the largest share in 2026, as library kits, panels, and sequencing chemistry are reordered with every run and the large fleet of sequencers installed during the pandemic keeps reagent use steady. Software & bioinformatics is projected to record the highest CAGR, supported by labs short of bioinformatics staff that need automated analysis, the linking of genomic and clinical data, and AI-enabled epidemiology tools. Instruments are expected to grow more slowly as laboratories draw on existing capacity.
By sequencing approach, the pathogen genomics and genomic surveillance market is segmented into whole-genome sequencing, targeted & amplicon sequencing, and metagenomic sequencing. Whole-genome sequencing leads in 2026, as it is the reference method for viral variant tracking, foodborne outbreak investigation, and resistance surveillance, and gives the full-genome resolution needed to link cases. Metagenomic sequencing is set to grow the fastest, driven by clinical metagenomic tests, unbiased screening of wastewater and traveler samples, and the need to catch new or unexpected pathogens.
By platform, the pathogen genomics and genomic surveillance market is segmented into short-read and long-read sequencing. Short-read sequencing holds the larger share in 2026, given its high accuracy and throughput and its established place in public health laboratories that run large surveillance volumes on platforms from Illumina and others. Long-read sequencing is projected to post the higher CAGR, as portable and fast nanopore devices work in field and low-resource settings and long reads resolve complete genomes, plasmids, and resistance genes.
By pathogen type, the pathogen genomics and genomic surveillance market is segmented into viruses, bacteria, fungi, and parasites. Viruses account for the largest share in 2026, reflecting continued monitoring of SARS-CoV-2, H5N1 and other influenza strains, RSV, measles, mpox, and HIV. Bacteria are projected to grow the fastest, as whole-genome sequencing spreads in AMR surveillance, foodborne outbreak work, tuberculosis drug resistance testing, and hospital infection control. Fungi are also expected to grow strongly as surveillance of drug-resistant fungal pathogens expands.
By application, the pathogen genomics and genomic surveillance market is segmented into outbreak detection & public health surveillance, wastewater & environmental surveillance, clinical infectious disease diagnostics, antimicrobial resistance monitoring, food safety & One Health surveillance, and vaccine & drug development. Outbreak detection & public health surveillance holds the largest share in 2026, since national and regional public health laboratories sequence routinely for variant tracking and outbreak response. Wastewater & environmental surveillance is set to grow the fastest, supported by the scale of NWSS, multi-pathogen expansion of wastewater programs, and international support such as International Pathogen Surveillance Network (IPSN) grants. Clinical infectious disease diagnostics should also grow strongly on metagenomic testing.
By end user, the pathogen genomics and genomic surveillance market is segmented into public health laboratories & government agencies, hospitals & clinical laboratories, academic & research institutes, pharmaceutical & biotechnology companies, and food, agriculture & animal health organizations. Public health laboratories & government agencies hold the largest share in 2026, as national and regional agencies run most genomic surveillance programs. Hospitals & clinical laboratories are projected to grow the fastest, driven by metagenomic diagnostics, sequencing to investigate healthcare-associated outbreaks, and resistance testing, which depend less on public health budgets.
Regional Analysis
The report covers North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa, spanning 21 countries and four rest-of-region groups. The regional analysis considers surveillance programs and funding, clinical adoption, wastewater monitoring, capacity-building support, and local suppliers.North America is expected to hold the largest share of the global market in 2026, supported by large public health programs such as NWSS and the CDC Advanced Molecular Detection program, advanced clinical laboratories, and providers such as Illumina, Thermo Fisher Scientific, Twist Bioscience, and Karius. Since 2021, the CDC's airport program has tested voluntary traveler nasal swabs and aircraft and terminal wastewater at nine U.S. international airports for more than 30 viral and bacterial targets. Uncertain funding beyond fall 2026 may slow near-term growth, while Canada adds demand through national wastewater and genomic programs.
Asia-Pacific is projected to grow at the highest CAGR, driven by large populations, frequent zoonotic and respiratory threats, investment in public health and pandemic preparedness, and rising sequencing capacity. China is expected to lead the region on large public health and research programs and domestic sequencing suppliers, with strong growth also expected across Japan, Singapore, South Korea, Australia, and India. Europe holds a significant share through ECDC coordination, strong national programs, EU wastewater initiatives, and suppliers such as Oxford Nanopore Technologies, QIAGEN, and Eurofins; the UK Health Security Agency runs one of the most advanced programs, and Berlin hosts the WHO hub that houses IPSN. Latin America, led by Brazil and Mexico, and the Middle East & Africa, supported by the Africa Pathogen Genomics Initiative and public health genomics investment in the Gulf countries, hold smaller shares but are expected to grow strongly.
Competitive Landscape
The report provides a detailed review of the competitive landscape, covering key growth strategies, competitive benchmarking, the competitive dashboard, and market share/rank analysis by key player for 2025. Company profiles include business and financial overviews, portfolios, strategic developments, and SWOT analyses.A small group of sequencing platform providers holds a significant share of the moderately consolidated pathogen genomics and genomic surveillance market, alongside reagent and panel suppliers such as Twist Bioscience, bioinformatics vendors, clinical metagenomic testing companies such as Karius, and surveillance service providers. Competition rests on turnaround time, throughput and cost per sample, portability, pathogen coverage, analysis and data-sharing tools, clinical regulatory status, and the ability to support public agencies and training programs. Leading players are developing multi-pathogen panels, portable sequencing, automated analysis, and clinical tests, often in partnership with public agencies and clinical laboratories. Recent developments include Karius' April 2026 launch through Mayo Clinic Laboratories, the WHO-hosted IPSN's second USD 1.8 million round of catalytic grants in April 2026, and Ginkgo Bioworks' agreement to sell its biosecurity business, which reflects the restructuring of pandemic-era surveillance services.
Key companies profiled in the report include Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), Oxford Nanopore Technologies plc (U.K.), QIAGEN N.V. (Netherlands), Twist Bioscience Corporation (U.S.), Eurofins Scientific SE (Luxembourg), Karius, Inc. (U.S.), and MGI Tech Co., Ltd. (China).
How This Report Helps
- Provides reliable market size estimates and long-term forecasts for the global pathogen genomics and genomic surveillance market.
- Explains how public health genomics, emerging threats, wastewater monitoring, and AMR and food safety sequencing are shaping demand.
- Assesses the impact of post-pandemic funding cliffs, workforce gaps, and data-sharing barriers.
- Identifies high-growth opportunities across offering, sequencing approach, platform, pathogen type, application, end user, and region.
- Tracks clinical metagenomics, portable long-read sequencing, One Health surveillance, and AI-enabled genomic epidemiology.
- Benchmarks leading companies by portfolio and strategic developments.
- Supports product planning, partnering, and market entry decisions for suppliers and investors.
Key Questions Answered
- How big is the global pathogen genomics and genomic surveillance market today, and how will it grow through 2036?
- What are the main drivers, restraints, opportunities, challenges, and trends shaping the market?
- How is genomic surveillance moving from COVID-19 response to routine multi-pathogen programs?
- How will public health funding decisions in the U.S. and elsewhere affect demand?
- Which offering, sequencing approach, platform, pathogen type, application, and end-user segments will grow the fastest?
- How quickly will clinical metagenomic sequencing be adopted in hospitals?
- Which regions and countries offer the most attractive business opportunities?
- Who are the leading companies in the market, and how do they compare on technology and services?
Table of Contents
1. Introduction
2. Research Methodology
4. Market Overview
5. Pathogen Genomics and Genomic Surveillance Market, by Offering
6. Pathogen Genomics and Genomic Surveillance Market, by Sequencing Approach
7. Pathogen Genomics and Genomic Surveillance Market, by Platform
8. Pathogen Genomics and Genomic Surveillance Market, by Pathogen Type
9. Pathogen Genomics and Genomic Surveillance Market, by Application
10. Pathogen Genomics and Genomic Surveillance Market, by End User
11. Pathogen Genomics and Genomic Surveillance Market, by Geography
12. Competitive Landscape
13. Company Profiles
14. Appendix
LIST OF TABLES
LIST OF FIGURES
Companies Mentioned
- Illumina, Inc.
- Thermo Fisher Scientific Inc.
- Oxford Nanopore Technologies plc
- QIAGEN N.V.
- Twist Bioscience Corporation
- Eurofins Scientific SE
- Karius, Inc.
- MGI Tech Co., Ltd.
